Evidence map›Paper›PMID 29030222›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2017

Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment.

Shweta Sharma, Aman P Mann, Tarmo Mölder, Venkata Ramana Kotamraju, Robert Mattrey, Tambet Teesalu, Erkki Ruoslahti

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Shweta SharmaSanford-Burnham-Prebys Medical Discovery Institute, Cancer Research Center, La Jolla, CA, USA.
Aman P MannSanford-Burnham-Prebys Medical Discovery Institute, Cancer Research Center, La Jolla, CA, USA.
Tarmo MölderLaboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu 50411, Estonia.
Venkata Ramana KotamrajuSanford-Burnham-Prebys Medical Discovery Institute, Cancer Research Center, La Jolla, CA, USA; Center for Nanomedicine and the Department of Cell, Molecular and Developmental Biology, University of California, Santa Barbara, CA, USA.
Robert MattreyRadiology, Advanced Imaging Research Center, UT Southwestern Medical Center, Dallas, TX, USA.
Tambet TeesaluSanford-Burnham-Prebys Medical Discovery Institute, Cancer Research Center, La Jolla, CA, USA; Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu 50411, Estonia; Center for Nanomedicine and the Department of Cell, Molecular and Developmental Biology, University of California, Santa Barbara, CA, USA.
Erkki RuoslahtiSanford-Burnham-Prebys Medical Discovery Institute, Cancer Research Center, La Jolla, CA, USA; Center for Nanomedicine and the Department of Cell, Molecular and Developmental Biology, University of California, Santa Barbara, CA, USA. Electronic address: ruoslahti@sbpdiscovery.org.
Cancer Research Center · USDiscovery Institute · USSanford Burnham Prebys Medical Discovery Institute · USThe University of Texas Southwestern Medical Center · USUniversity of Tartu · EE

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael Jackson · 1985 to 2026
$107.2M
A nanosystem for tumor treatment and imagingR01CA188883 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI RUOSLAHTI, ERKKI · 2014 to 2018
$2.0M
Tumor Penetrating Peptides for Cancer TargetingR01CA152327 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI RUOSLAHTI, ERKKI · 2011 to 2015
$2.0M
A NOVEL TARGETED DELIVERY SYSTEM FOR CANCER TREATMENT AND DIAGNOSISR44CA183287 · NCI · ENDURX PHARMACEUTICALS, INC. · PI BRAMHILL, DAVID, RUOSLAHTI, ERKKI · 2014 to 2016
$1.7M
NCI NIH HHS P30 CA030199NCI NIH HHS R01 CA152327NCI NIH HHS R01 CA188883NCI NIH HHS R44 CA183287Wellcome Trust
6 · The paper itself

Abstract

Anti-angiogenic and vascular disrupting therapies rely on the dependence of tumors on new blood vessels to sustain tumor growth. We previously reported a potent vascular disrupting agent, a theranostic nanosystem consisting of a tumor vasculature-homing peptide (CGKRK) fused to a pro-apoptotic peptide [

Indexed as

AnimalsBreast NeoplasmsCell Line, TumorDrug Resistance, NeoplasmHumansMice, Inbred BALB CMice, NudeNanoparticlesNeovascularization, PathologicPeptide LibraryPeptidesPeptide LibraryPeptidesDrug resistanceIntegrinsPhage displayTumor angiogenesisTumor homing peptide

Identifiers

PMID29030222
PMCPMC5819600
OpenAlexW2761852548

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.